Skip to Content

89bio Inc Ordinary Shares ETNB

Morningstar Rating
$8.63 −0.34 (3.79%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ETNB is trading at a 311% premium.
Price
$8.58
Fair Value
$17.29
Uncertainty
Extreme
1-Star Price
$465.21
5-Star Price
$6.84
Economic Moat
Dbnc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ETNB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$8.97
Day Range
$8.599.06
52-Week Range
$6.5822.93
Bid/Ask
$8.16 / $9.50
Market Cap
$849.05 Mil
Volume/Avg
806,351 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
70

Comparables

Valuation

Metric
ETNB
PLRX
DYN
Price/Earnings (Normalized)
Price/Book Value
1.672.115.04
Price/Sales
3,678.63
Price/Cash Flow
Price/Earnings
ETNB
PLRX
DYN

Financial Strength

Metric
ETNB
PLRX
DYN
Quick Ratio
19.5515.952.41
Current Ratio
20.0416.122.53
Interest Coverage
−31.54−138.69
Quick Ratio
ETNB
PLRX
DYN

Profitability

Metric
ETNB
PLRX
DYN
Return on Assets (Normalized)
−28.84%−23.39%−77.53%
Return on Equity (Normalized)
−32.23%−25.61%−94.92%
Return on Invested Capital (Normalized)
−33.57%−29.08%−88.19%
Return on Assets
ETNB
PLRX
DYN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTfxhgtjqGyyz$586.1 Bil
VRTX
Vertex Pharmaceuticals IncFtwshxwfRkpjbp$113.7 Bil
REGN
Regeneron Pharmaceuticals IncZrdfbnnsjJzvqzdz$108.2 Bil
MRNA
Moderna IncBklfbpnprPqzd$50.9 Bil
ARGX
argenx SE ADRFwqnvhytXbxnn$22.0 Bil
BNTX
BioNTech SE ADRQmmkmlcbTyhj$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncRcdybjbhfDlkbtw$18.9 Bil
BMRN
Biomarin Pharmaceutical IncQgqlhsshFhkcxv$14.6 Bil
INCY
Incyte CorpGhjcyrhftDgzjcw$12.8 Bil
RPRX
Royalty Pharma PLC Class AWxnnqxfhtVhpkpgt$12.3 Bil

Sponsor Center